Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Cluster Headache
Interventions
0.143 mg/kg Psilocybin or 10 mg Psilocybin, 0.0143 mg/kg Psilocybin or 1 mg Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
West Haven, Connecticut
Enrolling by invitation Phase 1 Interventional Accepts healthy volunteers

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

NCT07180108
Conditions
Psilocybin, Music Intervention
Interventions
Psilocybin (high dose), Playlist 1, Playlist 2, Playlist 3, Playlist 4, Playlist 5
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Effects of Psilocybin in Major Depressive Disorder

NCT03181529
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Results available

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595
Conditions
Depressive Symptoms, Anxiety, Cancer
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alcohol Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

Psilocybin and Spiritual Practice

NCT00802282
Conditions
Healthy
Interventions
psilocybin, Intensity of support for spiritual practice, Number of sessions
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obsessive-Compulsive Disorder
Interventions
Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
Interventions
Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
25 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Albuquerque, New Mexico • Brooklyn, New York • New York, New York + 1 more
Conditions
PTSD
Interventions
Psilocybin 15mg, Psilocybin 25mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin for Treatment of OCD-2

NCT06992999
Conditions
Obsessive - Compulsive Disorder
Interventions
Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Francisco A Moreno
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994
Conditions
Nicotine Dependence
Interventions
Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Opioid Use Disorder
Interventions
Psilocybin (high dose), psilocybin (low dose)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Migraine Headache
Interventions
High Dose Psilocybin, Low Dose Psilocybin, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Demoralization
Interventions
Psilocybin, Ketamine
Drug
Lead sponsor
Charles S. Grob, M.D.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Greenbrae, California • Los Angeles, California • San Francisco, California + 2 more
Conditions
Obsessive-compulsive Disorder (OCD)
Interventions
Psilocybin 100 mcg/kg, Psilocybin 300 mcg/kg, Lorazepam 1 mg
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Anorexia Nervosa
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Psychedelics in Healthy Older Adults With Low Well-being

NCT07386730
Conditions
Anhedonia in Healthy Volunteers, Older Adults (50-90 Years)
Interventions
Psilocybin (drug), Dextromethorphan (DXM)
Drug
Lead sponsor
Jennifer Mitchell
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Conditions
Stuttering
Interventions
Psilocybin, Speech therapy
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York